Direct compression of CIP Station Pharma Grade API into an immediate-release tablet is controlled primarily by particle size, moisture, and consolidation behavior rather than by API class alone. Particle size is adjusted so that the API D90 is not more than 100 µm and the D50 is between 10 µm and 40 µm by laser diffraction Ph.Eur 2.9.31. A production-scale Korsch XL 400 or FETTE 3200i rotary press with 43–65 stations can sustain 80,000–250,000 tablets/h only when the final blend maintains a bulk density between 0.45 g/mL and 0.65 g/mL and a compressibility index below 20% per USP <1174>. Representative direct-compression frames for low-dose APIs place the active component at 2.0–10.0 wt%, microcrystalline cellulose at 45.0–55.0 wt%, lactose monohydrate at 35.0–45.0 wt%, croscarmellose sodium at 2.0–4.0 wt%, colloidal silicon dioxide at 0.5–1.0 wt%, and magnesium stearate at 0.25–1.0 wt%. Compression force is set between 8 kN and 16 kN for 7–10 mm round tooling, targeting tablet hardness of 60–120 N and friability not greater than 1.0% after 100 revolutions under USP <1216>. Dissolution is monitored using USP <711> Apparatus II at 50 rpm in 900 mL of 37 °C ± 0.5 °C phosphate buffer pH 6.8, provided the API is BCS Class I or III; otherwise pH-solubility data determine the medium. Content uniformity is assessed under USP <905>, requiring an acceptance value not greater than 15.0 for 10 dosage units at release. Elemental impurities are controlled according to ICH Q3D, and residual solvent screening follows USP <467> and ICH Q3C. The terminal product is an immediate-release tablet with a target disintegration time below 15 min in USP <701> medium at 37 °C ± 2 °C.

Why Does Capsule Fill Weight Drift During High-Speed Encapsulation?

With CIP Station Pharma Grade API in powder-filled hard gelatin or hypromellose capsules, fill weight drift on a Bosch GKF 2600 or MG2 Tekna tamping-pin machine is typically linked to charge bed porosity, API lot-to-lot moisture variation, and electrostatic charge. The blend for a size 3 capsule often contains 5.0–10.0 wt% API, 80.0–90.0 wt% lactose monohydrate or mannitol, 2.0–5.0 wt% sodium starch glycolate, 0.5–1.0 wt% colloidal silicon dioxide, and 0.5–1.5 wt% magnesium stearate. The fill target is set by tamping-pin compression force, not by gravimetric weight alone. Tamping pin insertion depth of 8–12 mm at a dosing disk speed of 50–100 rpm produces plug densities in the range of 0.55–0.75 g/cm³. Moisture is maintained below 2.0% by loss on drying USP <731> because hygroscopic API lots can reduce powder flow through the feed hopper and cause fill weight relative standard deviation to exceed 3.0%. Capsule shell moisture is separately held at 12–16% w/w; lower moisture increases brittleness and splitting during high-speed closing. Dissolution of the filled capsules is assessed with USP <711> Apparatus I or II, with sinkers for low-density formulations. Content uniformity follows USP <905>, and blend uniformity is verified before filling under 21 CFR 211.110. The terminal product is a hard-shell capsule with disintegration below 15 min under USP <701>.

High-shear wet granulation of CIP Station Pharma Grade API is justified when direct compression cannot deliver acceptable content uniformity at an API load below 2.0 wt% or when the API is sensitive to segregation in a low-shear tumbling mixer. Dry blending is performed in a Collette Gral-75 or equivalent 75 L vertical-shaft high-shear granulator at impeller speed 300 rpm and chopper speed 1,500 rpm for 2 min. A binder solution of 5.0 wt% povidone K30 in purified water is added at 0.5 kg/min to a total granulating fluid load of 25–35 wt% relative to dry powder weight. Wet massing continues until the impeller torque reaches 15–25 N·m, a range that correlates with granule mean size and final tablet hardness more closely than fixed massing time in scale-up records. The wet granulate is discharged through a 6.35 mm mesh and dried in a Glatt GPCG-60 fluid-bed dryer with inlet air at 55–65 °C and product temperature held between 35 °C and 40 °C to avoid degrading heat-sensitive API fractions. Final loss on drying is controlled at 1.5–2.5% by USP <731>, and milled granules are passed through a 0.8–1.25 mm conical screen using a Quadro Comil at 1,000 rpm. The resulting granule size distribution is checked by sieve analysis USP <786>, with a typical D50 between 120 µm and 180 µm and fines below 20 wt%. Extragranular crospovidone is added at 2.0 wt%, followed by magnesium stearate at 0.5 wt% for 2 min. The final granulate can be fed to a rotary tablet press at 10–20 kN for film-coated oral tablets or filled directly into foil-lined sachets as a granule product. Coating with aqueous Opadry II to 3.0–4.0% weight gain provides moisture protection and taste masking. Drug release is verified by USP <711>, residual solvents by USP <467>, and degradation impurities by ICH Q3B.

Roller Compaction, Ribbon Density, and Granule Size Control

Dry granulation by roller compaction is used for CIP Station Pharma Grade API when moisture exposure during aqueous wet granulation is unacceptable or when the API exhibits poor compactability after rewetting. A Fitzpatrick CCS 220 or Alexanderwerk WP 120 roller compactor configured with smooth or knurled rolls compresses a pre-blend into ribbons at roll pressure 4–8 kN/cm, roll speed 6–10 rpm, and roll gap 2.0–3.0 mm. The pre-blend contains API at 5.0–20.0 wt%, microcrystalline cellulose at 30.0–50.0 wt%, lactose monohydrate at 30.0–50.0 wt%, croscarmellose sodium at 2.0–3.0 wt%, and a pre-lubricant portion of magnesium stearate at 0.5–1.0 wt% to reduce roll adhesion. Ribbon solid fraction is maintained between 0.60 and 0.70 by helium pycnometry or calculated from ribbon thickness and mass. Lower solid fraction increases fines during milling, while higher solid fraction can reduce tablet tensile strength due to loss of compaction potential. Milling is performed with a grate bar and rotor at 50–80 rpm, producing granules screened to 0.8–1.25 mm. After granulation, the remaining extragranular disintegrant 1.0–2.0 wt% and magnesium stearate 0.25–0.5 wt% are added in a tumble blender at 12 rpm for 2 min. Tablet hardness is evaluated at 60–100 N, dissolution by USP <711>, and content uniformity by USP <905>. The terminal product is typically an immediate-release tablet or a scored tablet with no solvent residue, which simplifies USP <467> compliance. Published data for this specific configuration is limited at extreme API loadings above 25 wt% because roll sticking and loss of blend flow dominate.

Oral suspension compounding with CIP Station Pharma Grade API begins with particle size reduction by air-jet milling to a D90 below 25 µm to minimize viscosity and sedimentation. The suspending vehicle contains microcrystalline cellulose and carboxymethylcellulose sodium at 1.0–2.0 wt%, sorbitol at 20.0–30.0 wt%, glycerin at 10.0–20.0 wt%, sodium benzoate at 0.1–0.2 wt%, and polysorbate 80 at 0.05–0.1 wt% as wetting agent. The API is dispersed under high-shear at 3,000 rpm for 15 min, then pH is adjusted to 4.5–5.5 with citric acid or sodium citrate to reduce zeta-potential drift. Viscosity is measured with a Brookfield RVT at 25 °C, spindle 2, 30 rpm, and controlled between 150 cP and 300 cP to provide pourability and dose uniformity. The suspension is filled into amber PET bottles with child-resistant closures at 100 mL or 150 mL volumes and dosed with graduated syringes. Release testing includes assay and dose uniformity under USP <905>, pH, and microbial limits USP <61> and USP <62>. Absence of specified objectionable organisms is documented under USP <1111>, and preservative efficacy is verified by USP <51>. The terminal product is a ready-to-use oral suspension with shelf life determined by antimicrobial effectiveness rather than by chemical stability alone.

When Terminal Sterilization Is Applied to Aqueous Injectable Formulations

Terminally sterilized aqueous injections containing CIP Station Pharma Grade API require a formulation route that separates bulk solution preparation from sterile filling and thermal sterilization. The bulk solution is prepared in a closed 316L stainless steel vessel at an API concentration of 5.0–20.0 mg/mL, adjusted to pH 6.0–7.0 with 0.1 N hydrochloric acid or sodium hydroxide as needed. Tonicity is corrected to 250–350 mOsm/kg with sodium chloride at 9.0 mg/mL. Nitrogen blanketing is applied when forced degradation studies show oxidative sensitivity. Pre-filtration bioburden is held below 10 CFU/100 mL, enumerated by membrane filtration per USP <61>. The bulk is double-filtered through a 0.45 µm prefilter and a 0.22 µm sterilizing-grade PVDF filter, with filter integrity tested before and after use by bubble point or diffusive flow per ASTM F838-20. Filling occurs in a restricted-access barrier system or isolator within an ISO 14644-1 Class 5 zone equivalent to EU GMP Annex 1 Grade A. Terminal sterilization is performed in a steam-air autoclave at 121 °C for 15 min, delivering an F0 value not less than 12 min per ISO 17665-1:2006. Post-sterilization testing includes sterility by USP <71>, bacterial endotoxin by USP <85>, particulate matter by USP <788>, and visible particulates by USP <790>. Endotoxin acceptance is calculated from K/M, where K = 5 EU/kg for parenterals and M is the maximum bolus dose in mL/kg. A 10 mL dose in a 70 kg adult yields M = 0.143 mL/kg and a limit of 35 EU/mL. For a 500 mL infusion, the corresponding limit is 0.7 EU/mL. pH drift is logged after terminal heating because autoclaving may shift pH by 0.2–0.4 units. The terminal product is a ready-to-use liquid in Type I borosilicate glass vials of 2 mL, 5 mL, or 10 mL, with glass tested under USP <660> and elastomeric closures tested under USP <381>.

Lyophilization Requires Collapse-Temperature-Linked Shelf Control

Where CIP Station Pharma Grade API degrades under autoclave heat or hydrolyzes in aqueous solution at elevated pH, freeze-drying in Type I glass vials becomes the selected injectable route. The formulation is held at half-fill volume in 5 mL or 10 mL vials and contains the API at 5.0–20.0 mg/mL with bulking agent mannitol at 40.0–80.0 mg/mL and cryoprotectant sucrose or trehalose at 10.0–30.0 mg/mL. Freezing is performed on a Telstar LYOBETA or SP Scientific LyoStar 3 with shelf cooling to −45 °C at 0.5–1.0 °C/min and hold for 2–4 h. Primary drying shelf temperature is set 3–5 °C below the collapse temperature measured by freeze-dry microscope. For a representative collapse temperature of −32 °C, shelf temperature is held at −15 °C to −10 °C with chamber pressure at 0.10–0.20 mbar. Secondary drying is conducted at 25–40 °C for 4–8 h until cake moisture by Karl Fischer USP <921> Method I falls to ≤1.0%. Vials are stoppered under vacuum or partial nitrogen to reduce headspace oxygen and sealed with aluminum flip-off seals. Sterility is verified by USP <71>, bacterial endotoxin by USP <85>, and particulate matter by USP <788> after reconstitution. The terminal product is a lyophilized powder or porous cake labeled for reconstitution with Sterile Water for Injection to the original fill volume, producing a solution free of visible particulates under USP <790>. Batch records specify that the ice sublimation rate must not exceed the vapor removal capacity of the condenser, otherwise collapse or meltback occurs and the batch fails visual appearance and residual moisture.